The Portugal National Health Service (SNS) has hit a historic spending ceiling on pharmaceuticals — €4.42 billion in 2025 — driven chiefly by breakthrough oncology drugs, treatments for rare diseases, and next-generation diabetes medication. For the first time, hospital drug bills exceeded €2.5 billion, a jump of 11.2% year-on-year, while household out-of-pocket costs climbed past €966 million.
Why This Matters
• Hospital drug costs surged 11.2% to €2.52 billion, with oncology alone accounting for €864.5 million.
• Families paid €966 million for medicines — €45 million more than in 2024 — even with state subsidies in place.
• Weight-loss drugs like Mounjaro and Wegovy drove €613,000 in daily private spending, totaling €130 million in 2025, with zero SNS coverage.
• Budget 2026 targets a 6% cut in drug procurement, banking on generic uptake and centralized purchasing, despite continued innovation costs.
The Innovation Premium
Portugal-based hospitals are now absorbing the financial impact of what regulators at Infarmed — the national medicines authority — describe as an era of therapeutic breakthroughs. Cancer medicines dominate: oncology treatments claimed over one-third of hospital pharmaceutical budgets, rising 16% to €864.5 million. Orphan drugs for rare conditions jumped 34.1% to €465 million, while immunomodulators — which reprogram immune responses — added another €78.3 million to the ledger.
Anti-diabetes agents led outpatient subsidies at €478.9 million, up 14.7%. The blood thinner apixaban posted the steepest single-drug increase, soaring 70.9% to €66.6 million as prescribers shifted away from older anticoagulants. Vaccines saw a 69.8% spike to €85.5 million, reflecting expanded immunization programs.
Helder Filipe, president of the Ordem dos Farmacêuticos (Portugal's pharmacists' council), told reporters the figures were predictable. "We're solving problems that until now couldn't be tackled or weren't addressed at all," he said. "All these medicines are very expensive, generating double-digit annual increases in both hospital and outpatient spending — something we didn't see before."
In the first quarter of 2026, hospital drug bills hit €693.4 million, a 7.6% rise Infarmed attributes directly to innovative therapies entering the formulary.
What This Means for Residents
The spending surge translates into a dual burden: higher state outlays and rising household costs. Portuguese families spent an average of €4.74 per prescription package in 2025, while the SNS covered €9.60 — a growing imbalance as innovative drugs carry premium price tags. In the opening three months of 2026, households paid €243.1 million, up €3.2 million from the prior year.
Outpatient prescriptions totaled 203.9 million packages in 2025, with cholesterol-lowering statins leading utilization at 21.3 million units, followed by paracetamol and beta-blockers for hypertension. Generic drugs captured 50.9% of the ambulatory market — rising to 63.7% in segments where generics are available — yet that share has plateaued, a trend Filipe flagged as a sustainability concern.
"We need mechanisms that keep costs as low as possible without limiting access to therapeutic innovation," he said. "One of the tools we have is greater use of generics."
The Weight-Loss Drug Phenomenon
A new spending frontier emerged in 2025: GLP-1 receptor agonists marketed for weight management. Eli Lilly's Mounjaro and Novo Nordisk's Wegovy accounted for €130 million in out-of-pocket purchases last year, with consumers buying roughly 1,200 packages daily. In just the first quarter of 2026, sales topped €55.2 million — over 167,000 Mounjaro units and 42,000 Wegovy packages — at an average daily private burn rate of €613,000.
Neither drug receives SNS subsidies, placing the full cost on individuals. Demand remains robust despite price barriers, reflecting both clinical obesity management and off-label cosmetic use.
Geographic and Clinical Hotspots
ULS Santa Maria in Lisbon logged the highest institutional drug spend at €304.9 million, followed by ULS de Coimbra (€235.9 million) and ULS São João in Porto (€223.4 million). Outpatient clinics and external dispensing accounted for 42.7% of hospital pharmaceutical costs (€1.08 billion), with day-hospital infusions adding €900.4 million and inpatient wards €231.4 million.
Primary care saw the steepest relative jump: a 66.5% increase to €97.8 million, driven by expanded chronic disease management in community health centers.
Government Strategy: Cost Controls Amid Innovation
The Portugal Cabinet's 2026 budget imposes a 6% reduction in drug and clinical consumables procurement — over €200 million in cuts — while the Ministry of Health targets progressive savings of €6.3 million in 2026, €10.1 million in 2027, and €13 million by 2028. Officials insist the targets reflect efficiency gains, not rationing, with five intervention levers:
Polypharmacy reduction: Clinical audits to curb excessive multi-drug regimens in elderly patients.
Waste elimination: Tighter inventory control and unused-medication return programs.
Therapeutic targeting: Focus on high-impact drug classes and active ingredients.
Subsidy reform: Revision of special reimbursement rules for outpatient prescriptions.
Centralized purchasing: Thirty procurement procedures launching in 2026 for framework agreements on medicines and devices, leveraging EU cooperative buying networks.
Health Minister Ana Paula Martins acknowledged Portugal must prepare for potential international price increases but downplayed immediate alarm. A February 2026 regulatory report recommended Portugal shift toward confidential managed-entry agreements tied to net price rather than rigid list-price anchors, aligning with broader European practice.
The 2025 SNS statute revision eliminated a non-clinical barrier to generic dispensing, aiming to accelerate substitution at pharmacy counters. Biosimilars — biologic drug copies whose patents expired — achieved a 53.8% hospital market share, though room for expansion remains.
Comparative Context: European Approaches
Across the EU, countries like Denmark and France impose price cuts, while Germany and the Netherlands use reference pricing tied to therapeutic equivalents. Italy employs risk-sharing contracts for high-cost cancer drugs. Portugal is embedding similar cost-management strategies through centralized procurement and cross-border purchasing alliances, positioning itself within broader European pharmaceutical governance.
The Balancing Act
Hospital administrators and pharmacist representatives caution that deeper cuts risk colliding with demographic reality: an aging population, rising chronic disease prevalence, and accelerating innovation pipelines. The Portuguese Association of Hospital Administrators warned that spending growth does not equal waste but reflects access to costlier, more effective therapies and expanding patient volumes.
Filipe stressed the sector must confront a new normal. "We have to discuss how to keep the system sustainable and have mechanisms to spend less than we are, while maintaining access to medicines," he said. "We need to prepare the SNS and the entire health system for this new reality."
Regulatory timelines compound pressure: pharmaceutical companies took an average of nine months to submit new drugs for evaluation in recent cycles, with Infarmed requiring 11 months to assess and decide — delays that can postpone both cost certainty and clinical availability.
Insulin Pump Breakthrough
One bright spot: in 2025, Portugal moved to 100% state coverage of insulin pumps for SNS beneficiaries dispensed through community pharmacies, eliminating a significant out-of-pocket barrier for Type 1 diabetes management. The policy shift, highlighted by Infarmed, marks a rare expansion of coverage amid broader cost-containment efforts.
The Road Ahead
With hospital drug spending accelerating at 7.6% through early 2026 and innovation showing no sign of slowing — particularly in oncology, rare diseases, and metabolic disorders — Portugal faces a policy tightrope. The government's bet on generic substitution, bulk purchasing, and waste reduction must deliver tangible savings without stalling access to life-extending therapies. For residents, the equation remains stark: either the state absorbs mounting bills through tax revenue, or households shoulder a growing share of pharmaceutical costs in a system built on universal coverage. The next 18 months will test whether efficiency gains can genuinely stretch a finite budget, or whether structural reforms — including price caps, mandatory discounts, or therapeutic rationing — become unavoidable.
